FY2026 EPS Estimates for Senseonics Raised by HC Wainwright

Senseonics Holdings, Inc. (NYSE:SENS - Free Report) - Equities researchers at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for Senseonics in a research note issued to investors on Tuesday, July 8th. HC Wainwright analyst S. Lee now forecasts that the company will earn ($0.05) per share for the year, up from their previous forecast of ($0.06). HC Wainwright has a "Buy" rating and a $1.40 price target on the stock. The consensus estimate for Senseonics' current full-year earnings is ($0.14) per share.

Several other analysts also recently commented on SENS. Wall Street Zen upgraded shares of Senseonics to a "sell" rating in a research report on Monday, May 12th. Mizuho started coverage on Senseonics in a research report on Thursday, April 10th. They set an "outperform" rating and a $2.00 target price on the stock.

Senseonics Stock Performance

NYSE:SENS traded down $0.01 during mid-day trading on Thursday, reaching $0.49. 3,750,012 shares of the stock were exchanged, compared to its average volume of 7,143,562. The company has a 50 day simple moving average of $0.54 and a 200-day simple moving average of $0.68. The stock has a market capitalization of $319.26 million, a P/E ratio of -3.75 and a beta of 0.92. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. Senseonics has a 1 year low of $0.25 and a 1 year high of $1.40.

Institutional Investors Weigh In On Senseonics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Raymond James Financial Inc. purchased a new position in shares of Senseonics during the fourth quarter valued at approximately $26,000. IFP Advisors Inc raised its holdings in Senseonics by 120.9% in the 1st quarter. IFP Advisors Inc now owns 47,500 shares of the company's stock valued at $31,000 after acquiring an additional 26,000 shares during the last quarter. CTC Alternative Strategies Ltd. acquired a new position in Senseonics in the 1st quarter valued at $31,000. HighTower Advisors LLC acquired a new position in Senseonics in the 4th quarter valued at $32,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Senseonics in the fourth quarter valued at $36,000. Hedge funds and other institutional investors own 12.36% of the company's stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.